Drug intelligence / Profile preview

M2 macrophages conditioned medium

Development stage
Unknown
Lead developer
Research Institute of Fundamental and Clinical Immunology
Modality
Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Local Injection, Topical, Intradiscal Injection, Intratumoral Injection, Intravenous Injection
01

Overview

M2 macrophages conditioned medium (M2-CM) is a cell-free biologic therapeutic consisting of the secretome of M2-polarized macrophages. Developed by the Research Institute of Fundamental and Clinical Immunology, it is produced by polarizing peripheral blood mononuclear cells into M2-like macrophages, which then secrete a complex mixture of neurotrophic, proangiogenic, and immunoregulatory factors. Key components identified in the secretome include vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), erythropoietin (EPO), and brain-derived neurotrophic factor (BDNF). The medium is administered intranasally to bypass the blood-brain barrier, aiming to reduce neuroinflammation and stimulate neuroregeneration. It has been clinically evaluated for treating specific language impairment (SLI), autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD) in children, as well as organic brain lesions and associated cognitive impairments in adults.

Other names
M2 macrophage secretomeM-2 macrophage secretomeM 2 macrophage secretomeM2-CMM-2-CMM 2-CMM2-conditioned mediaM-2-conditioned mediaM 2-conditioned media
02

Targets

BDNF (Brain-derived neurotrophic factor)EPO (Erythropoietin)IGF-1 (Insulin-like growth factor 1)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on M2 macrophages conditioned medium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on M2 macrophages conditioned medium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call